These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25892351)

  • 1. Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts.
    Brusselle GG; Bracke K; Lahousse L
    Lancet Respir Med; 2015 Jun; 3(6):416-7. PubMed ID: 25892351
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?
    Groenke L; Disse B
    Lancet Respir Med; 2015 Aug; 3(8):e26. PubMed ID: 26282478
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?--Authors' reply.
    Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord I
    Lancet Respir Med; 2015 Aug; 3(8):e27. PubMed ID: 26282479
    [No Abstract]   [Full Text] [Related]  

  • 4. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluticasone-vilanterol combination approved for COPD.
    Traynor K
    Am J Health Syst Pharm; 2013 Jun; 70(12):1008. PubMed ID: 23719869
    [No Abstract]   [Full Text] [Related]  

  • 6. Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses.
    Iqbal A; Barnes NC; Brooks J
    Clin Drug Investig; 2015 Oct; 35(10):685-8. PubMed ID: 26329916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breo Ellipta: An Inhaled Fluticasone/ Vilanterol Combination for COPD.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):69-71, 45-8. PubMed ID: 26839934
    [No Abstract]   [Full Text] [Related]  

  • 8. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
    Crim C; Calverley PMA; Anderson JA; Holmes AP; Kilbride S; Martinez FJ; Brook RD; Newby DE; Yates JC; Celli BR; Vestbo J;
    Respir Med; 2017 Oct; 131():27-34. PubMed ID: 28947039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vilanterol fluticasone and mortality in comorbid COPD GOLD B.
    Brusselle G
    Lancet; 2016 Apr; 387(10030):1791-2. PubMed ID: 27203487
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L; Kerwin E; Collison K; Nelsen L; Wu W; Yang S; Pascoe S
    Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG; Prosser TR
    Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
    Rodrigo GJ; Neffen H
    Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. vilanterol + fluticasone (RELVAR Ellipta). Asthma and COPD: yet another beta-2 agonist and corticosteroid combination.
    Prescrire Int; 2016 Apr; 25(170):94. PubMed ID: 27186620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lung study promising a breath of fresh air in research world.
    Limb M
    BMJ; 2015 Nov; 351():h6343. PubMed ID: 26613902
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ▼Relvar Ellipta for COPD.
    Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
    Kelly E
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):403-13. PubMed ID: 24909949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COPD 2017: A Year in Review.
    Crisafulli E; Torres A
    COPD; 2018 Apr; 15(2):118-122. PubMed ID: 29583021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial.
    Crim C; Anderson JA; Calverley PMA; Celli BR; Cowans NJ; Martinez FJ; Newby DE; Vestbo J; Yates JC; Brook RD
    Am J Respir Crit Care Med; 2020 May; 201(10):1307-1310. PubMed ID: 32017597
    [No Abstract]   [Full Text] [Related]  

  • 20. Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction.
    Antohe I; Antoniu SA; Gavrilovici C
    Expert Opin Pharmacother; 2018 Feb; 19(3):287-289. PubMed ID: 29271268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.